|
|
Proliferation
and aneusomy predict survival of young patients with astrocytoma grade II
Wessels PH, Hopman AH, Kubat B, Kessels AG, Hoving EW, Ummelen MI, Ramaekers
FC, Twijnstra A
Department of Neurology, Research Institute Growth and
Development (GROW), University Hospital Maastricht, The Netherlands.
PWES@SNEU.ZAM.NL
The clinical course of astrocytoma grade II (AII) is highly variable and not
reflected by histological characteristics.
As one of the best prognostic factors, higher age identifies rapid progressive A
II.
For patients over 35 years of age, an aggressive treatment is normally
propagated.
For patients under 35 years, there is no clear guidance for treatment choices,
and therefore also the necessity of histopathological diagnosis is often
questioned.
We studied the additional prognostic value of the proliferation index and the
detection of genetic aberrations for patients with A II.
The tumour samples were obtained by stereotactic biopsy or tumour resection and
divided into two age groups, that is 18-34 years (n=19) and > or =35 years
(n=28).
Factors tested included the proliferation (Ki-67) index, and numerical
aberrations for chromosomes 1, 7, and 10, as detected by in situ hybridisation
(ISH).
The results show that age is a prognostic indicator when studied in the total
patient group, with patients above 35 years showing a relatively poor
prognosis.
Increased proliferation index in the presence of aneusomy appears to identify a
subgroup of patients with poor prognosis more accurately than predicted by
proliferation index alone.
We conclude that histologically classified cases of A II comprise a
heterogeneous group of tumours with different biological and genetic
constitution, which exhibit a highly variable clinical course.
Immunostaining for Ki-67 in combination with the detection of aneusomy by ISH
allows the identification of a subgroup of patients with rapidly progressive A
II.
This is an extra argument not to defer stereotactic biopsy in young patients
with radiological suspicion of A II.
PMID: 12838313 [PubMed - indexed for MEDLINE]
Source:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12838313&dopt=Abstract
|